Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: bisphosphonate

RA Patients May Not Receive Needed Osteoporosis Screening & Treatment

Arthritis Care & Research  |  

New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…

Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis

Reuters Staff  |  

NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…

Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis

Will Boggs MD  |  

NEW YORK (Reuters Health)—Patients with polymyalgia rheumatica (PMR) and giant-cell arteritis (GCA) have similarly increased risks of fracture, compared with the general population, researchers have found. “It is of surprise that patients with GCA have a similar fracture risk to those with PMR,” Dr. Zoe Paskins from Keele University, in Staffordshire, told Reuters Health by…

Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

Will Boggs MD  |  

NEW YORK (Reuters Health)—Treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy, according to a meta-regression analysis of 14 clinical trials. “These results may be useful for the development of new osteoporosis treatments or when considering new populations or dosing regimens with existing treatments,” Dr. Douglas C. Bauer from the University…

Hip Fractures Increasing in Older U.S. Women

Cheryl Platzman Weinstock  |  

(Reuters Health)—The incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients. Hip fracture rates declined each year from 2002–2012, the researchers found. But starting in 2013, hip fracture rates leveled off and were higher than expected….

Ethics Forum: A Physician’s Medical Error & the Patient’s Right to Know

Sian Yik Lim, MD, & Marcy B. Bolster, MD  |  

Case Ms. A is an 82-year-old woman who presented to the rheumatology office for evaluation of osteoporosis. She had been diagnosed with postmenopausal osteoporosis at age 62 after sustaining a right wrist fracture. She was started on alendronate 70 mg weekly and reported medication compliance. At age 79, she sustained an atraumatic right femur fracture….

Rheumatology Drug Updates: Opana ER Painkiller Pulled from U.S. Market; Upadacitinib to Treat RA, and More

  |  

Opana ER Pulled from U.S. Market Last month, the U.S. Food and Drug Administration (FDA) asked Endo Pharmaceuticals to remove oxymorphone hydrochloride extended release (Opana ER) from the U.S. market due to public health consequences related to abuse. The agency has concerns that the risks presented by the treatment do not outweigh its benefits.1 On…